Ignite Creation Date:
2024-05-05 @ 10:25 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01109706
Status:
COMPLETED
Last Update Posted:
2021-09-20
First Post:
2010-04-20
Brief Title:
Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Study Overview
Official Title:
Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PC-SCA-9
Brief Summary:
PCSK9 Proprotein convertase subtilisin kexin type 9 plays a key role in LDL-cholesterol LDLC metabolism by inhibiting LDL receptor LDLR at post-transcriptional level PCSK9 loss of function mutations are associated to decreased LDLC levels and a cardiovascular protection In this context the development of pharmacological inhibitors of PCSK9 in association with statins treatment represents a major therapeutic issue for LDLC modulation It was previously shown that PCSK9 plasmatic concentration correlated with plasmatic LDLC TG and glucose concentrations However no data are available on predictive value of PCSK9 plasmatic level concerning coronary disease severity
The main objective of this study is to determine whether plasmatic PCSK9 concentration is linked to coronary damage severity in patients with acute coronary syndrome
The main objective of this study is to determine whether plasmatic PCSK9 concentration is linked to coronary damage severity in patients with acute coronary syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None